Compare MI & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MI | NEPH |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 46.8M |
| IPO Year | N/A | 2004 |
| Metric | MI | NEPH |
|---|---|---|
| Price | $4.03 | $5.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.6K | ★ 75.5K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $662,718.00 | ★ $17,930,000.00 |
| Revenue This Year | N/A | $24.38 |
| Revenue Next Year | N/A | $10.16 |
| P/E Ratio | ★ N/A | $39.25 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $1.57 | $1.39 |
| 52 Week High | $8.61 | $6.42 |
| Indicator | MI | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 54.16 |
| Support Level | $2.59 | $4.50 |
| Resistance Level | $4.10 | $5.63 |
| Average True Range (ATR) | 0.23 | 0.58 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 95.05 | 52.67 |
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.